Global pharmaceutical behemoth Pfizer has announced the successful completion of its offering of $13.5 billion of senior unsecured notes.
The notes consist of: $1.25 billion of floating rate notes due 2011; $3.50 billion of 4.45% notes due 2012 ; $3.00 billion of 5.35% notes due 2015; $3.25 billion of 6.20% notes due 2019; and $2.50 billion of 7.20% notes due 2039.
The company intends to use the net offering proceeds for general corporate purposes, including funding a portion of the purchase price of the proposed Wyeth acquisition (Marketletters passim) and the refinancing of existing debt. Pfizer may also temporarily invest funds that are not immediately needed for these purposes in short-term marketable securities, the firm noted.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze